Talk

As someone with a strong pattern of hereditary breast/ovarian cancer in my family, it’s safe to say that I follow breast cancer news closely. Last month, there was big news from NCI about a study looking at tamoxifen and raloxifene for breast cancer prevention. Many trumpeted the summary findings — “raloxifene is as effective, with fewer side effects!” — but with studies like these, the devil lies in the details.

Denise Grady of the NYTimes dived into these details, and she breaks them down for us in her “second opinion” piece. This is the real news. Women making decisions about treating and preventing breast cancer are faced with a complex challenge of weighing risks, benefits, side effects, and peace of mind. Understanding the real details of your options — and figuring out what they mean to you, personally, can make all the difference in what you decide.

Technorati Tags: breast cancer, tamoxifen, raloxifene, drugs, prevention, treatment, side effects, STAR

This entry was posted on Tuesday, May 9th, 2006 at 10:18 am and is filed under Breast Cancer. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.